Abstract
Background Percutaneous drainage (PCD) is now the
first-line drainage method for liver abscess because of its
minimal invasiveness and high technical success rate.
However, this procedure has several disadvantages, such as
extra-drainage and self-tube removal. Recently, EUS-guided liver abscess drainage (EUS-AD) has been developed
However, only a few reports of EUS-AD have been reported. In addition, the clinical benefits of PCD and EUSAD have not been reported
Aims In the present study, the safety and feasibility of EUS-AD using fully covered SEMS (FCSEMS) and the clinical outcomes of EUS-AD and PCD were examined
retrospectively.
Methods Twenty-seven consecutive patients who underwent PCD or EUS-AD between April 2012 and April 2015 were included in this study. EUS-AD was performed using FCSEMS. In addition, to prevent stent migration, 7-Fr pig
tail plastic stent was placed within FCSEMS.
Results Technical success was achieved in all patients of both groups. Clinical success was 100 % in the EUS-ADgroup although it was 89 % in PCD group (P = 034).
Three adverse events were seen in the PCD group (selftube removal n = 1, tube migration n = 2), but no adverse events were seen in the EUS-AD group. The median hospital stay was significantly shorter in the EUS-AD group than in the PCD group (21 vs 41 days, P = 0.03).
Conclusion Because of the short hospital stay, the high clinical success rate, and the low adverse event rate compared to PCD, EUS-AD has potential as a first-line treatment for liver abscess.